The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Open accessAbstract
BACKGROUND: Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but require administration every 2 to 4 weeks. In a phase 2 trial, a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia. METHODS: In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio, 482 adults who had heterozygous familial hypercholesterolemia to receive subcutaneous injections of inclisiran sodium (at a dose of 300 mg) or matching placebo on days 1, 90, 270, and 450. The two primary end points were the percent change from baseline in the LDL cholesterol level on day 510 and the time-adjusted percent change from baseline in the LDL cholesterol level between day 90 and day 540. RESULTS: The median age of the patients was 56 years, and 47% were men; the mean baseline level of LDL cholesterol was 153 mg per deciliter. At day 510, the percent change in the LDL cholesterol level was a reduction of 39.7% (95% confidence interval [CI], -43.7 to -35.7) in the inclisiran group and an increase of 8.2% (95% CI, 4.3 to 12.2) in the placebo group, for a between-group difference of -47.9 percentage points (95% CI, -53.5 to -42.3; P<0.001). The time-averaged percent change in the LDL cholesterol level between day 90 and day 540 was a reduction of 38.1% (95% CI, -41.1 to -35.1) in the inclisiran group and an increase of 6.2% (95% CI, 3.3 to 9.2) in the placebo group, for a between-group difference of -44.3 percentage points (95% CI, -48.5 to -40.1; P<0.001). There were robust reductions in LDL cholesterol levels in all genotypes of familial hypercholesterolemia. Adverse events and serious adverse events were similar in the two groups. CONCLUSIONS: Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile. (Funded by the Medicines Company; ORION-9 ClinicalTrials.gov number, NCT03397121.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inclisiran lowered LDL-C by 47.9% in the 482 HeFH patients enrolled in ORION-9 at Day 510 [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study by Raal et al. focused on HeFH patients displayed an outlier position in the lower left quadrant of the funnel because it had both a small effect size and a wide standard error [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These results were confirmed in the phase 3 ORION-9 trial which showed a − 48% LDL-C reduction of inclisiran relative to placebo among 482 patients with HeFH [138].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran improved multiple lipid parameters including non-HDL-C, apoB, triglycerides and lipoprotein(a) in addition to LDL-C which makes it beneficial for complete lipid management [39, 43, 49].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationTherapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 820
Hepatocyte targeting via the asialoglycoprotein receptor
Ramírez-Cortés, F., & Ménová, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00652f · Cited by 55
New Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 62
Innovative developments and emerging technologies in RNA therapeutics
Halloy, F., Biscans, A., Bujold, K. E., Debacker, A. J., Hill, A. C., Lacroix, A., Luige, O., Strömberg, R., Sundström, L., Vogel, J., et al. (2022) · RNA Biology · doi:10.1080/15476286.2022.2027150 · Cited by 57
Management of Familial Hypercholesterolemia: Current Status and Future Perspectives
Lui, D. T. W., Lee, A. C. H., & Tan, K. C. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa122 · Cited by 63
Lipoprotein metabolism in familial hypercholesterolemia
Chemello, K., García‐Nafría, J., Gallo, A., Martı́n, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 60
Kosmas, C. E., Estrella, A. M., Skavdis, A., Genao, E. P., Martinez, I., & Guzman, E. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s230592 · Cited by 54
Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era
Xu, M., Zhang, K., & Song, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623674 · Cited by 55
Recent Advances on Familial Hypercholesterolemia in Children and Adolescents
Mainieri, F., Tagi, V. M., & Chiarelli, F. (2022) · Biomedicines · doi:10.3390/biomedicines10051043 · Cited by 53
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 58
Albosta, M. S., Grant, J. K., Taub, P., Blumenthal, R. S., Martin, S. S., & Michos, E. D. (2023) · Vascular Health and Risk Management · doi:10.2147/vhrm.s338424 · Cited by 51
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
Tang, Q., Fakih, H. H., Abideen, M. Z. U., Hildebrand, S. R., Afshari, K., Gross, K. Y., Sousa, J., Maebius, A., Bartholdy, C., Søgaard, P. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42714-4 · Cited by 51
Current landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
Banerjee, Y., Pantea Stoian, A., Cicero, A. F. G., Fogacci, F., Nikolic, D., Sachinidis, A., Rizvi, A. A., Janez, A., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1988568 · Cited by 54
Modern therapeutic approaches to liver-related disorders
Gardin, A., Remih, K., Gonzales, E. M., Andersson, E. R., & Strnad, P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.015 · Cited by 51
Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo
Biscans, A., Ly, S., McHugh, N., Cooper, D., & Khvorova, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.041 · Cited by 52
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 52
Biocatalytic Synthesis of Antiviral Nucleosides, Cyclic Dinucleotides, and Oligonucleotide Therapies
Giesen, K. J. D. V., Thompson, M. J., Meng, Q., & Lovelock, S. L. (2022) · JACS Au · doi:10.1021/jacsau.2c00481 · Cited by 54
Guan, B., Wang, A., & Xu, H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01927-z · Cited by 51
Clinical Updates in Coronary Artery Disease: A Comprehensive Review
Bottardi, A., Prado, G. F. A., Lunardi, M., Fezzi, S., Pesarini, G., Tavella, D., Scarsini, R., & Ribichini, F. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164600 · Cited by 60
First clinical experiences with inclisiran in a real-world setting
Mulder, J. W. C. M., Galema-Boers, A. M. H., & Roeters van Lennep, J. E. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.09.005 · Cited by 49
Chai, M., He, Y., Wang, Z., Han, X., Zhao, G., Ma, X., Qiao, P., Shi, D., Liu, Y., Han, W., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02797-8 · Cited by 48
Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges
Hofman, C. R., & Corey, D. R. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.005 · Cited by 56
Nanoparticles and siRNA: a new era in therapeutics?
Pérez-Carrión, M. D., Posadas, I., & Ceña, V. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107102 · Cited by 48
Cupido, A. J., & Kastelein, J. J. P. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa212 · Cited by 44
Self-citationExisting and emerging therapies for the treatment of familial hypercholesterolemia
Rosenson, R. S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100060 · Cited by 50
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
Vafai, S. B., Täubel, J., Ashdown, T., Patel, R. S., Diamondali, S., Cegla, J., Soran, H., Bashir, B., Abitbol, A., Gaudet, D., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2601283 · Cited by 54
Desai, N. R., Campbell, C., Electricwala, B., Petrou, M., Trueman, D., Woodcock, F., & Cristino, J. R. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00534-9 · Cited by 47
Nishikido, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01752-4 · Cited by 45
The Growing Class of Novel RNAi Therapeutics
Traber, G. M., & Yu, A. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000895 · Cited by 51
Gene therapy and genome editing for lipoprotein disorders
Gurevitz, C., Bajaj, A., Khera, A. V., Do, R., Schunkert, H., Musunuru, K., & Rosenson, R. S. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf411 · Cited by 50
Arnold, N., & Köenig, W. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01782-6 · Cited by 48
PCSK9: A emerging participant in heart failure
Xu, Q., Zhao, Y.-M., He, N.-Q., Gao, R., Xu, W., Zhuo, X.-J., Ren, Z., Wu, C., & Liu, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114106 · Cited by 47
Chen, Z., Gu, H., Mo, J., Yang, K., Jiang, Y., Yang, X., Wang, C., Xu, J., Meng, X., Jiang, Y., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.05.028 · Cited by 47
Brandts, J., Bray, S. L., Villa, G., Catapano, A. L., Poulter, N. R., Vallejo‐Vaz, A. J., & Ray, K. K. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100665 · Cited by 45
Self-citationMatsuda, S., Bala, S., Liao, J.-Y., Datta, D., Mikami, A., Woods, L. B., Harp, J. M., Gilbert, J. A., Bisbe, A., Manoharan, R. M., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04744 · Cited by 48
Vaccination in Atherosclerosis
Nettersheim, F. S., Vore, L. D., & Winkels, H. (2020) · Cells · doi:10.3390/cells9122560 · Cited by 47
Treatment of Dyslipidaemia in Children
Fiorentino, R., & Chiarelli, F. (2021) · Biomedicines · doi:10.3390/biomedicines9091078 · Cited by 46
Inclisiran in lipid management: A Literature overview and future perspectives
Scicchitano, P., Milo, M., Mallamaci, R., Palo, M. D., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112227 · Cited by 47
Kadlecová, Z., Kalíková, K., Tesařová, E., & Gilár, M. (2022) · Journal of Chromatography A · doi:10.1016/j.chroma.2022.463201 · Cited by 44
Engineered multi-domain lipid nanoparticles for targeted delivery
Liu, Z., Chen, J., Xu, M., Ho, S., Wei, Y., Ho, H., & Yong, K. (2025) · Chemical Society Reviews · doi:10.1039/d4cs00891j · Cited by 63
Sinning, D., & Landmesser, U. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01427-6 · Cited by 44
A Critical Review of the Efficacy and Safety of Inclisiran
Hardy, J., Niman, S., Pereira, E., Lewis, T., Reid, J., Choksi, R., & Goldfaden, R. F. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00477-7 · Cited by 44
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
Bejar, N., Tat, T. T., & Kiss, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01007-9 · Cited by 45
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
CRISPR-Cas System: The Current and Emerging Translational Landscape
Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 46
Protein-based nanoparticles for therapeutic nucleic acid delivery
Eweje, F., Walsh, M. L., Ahmad, K., Ibrahim, V., Alrefai, A., Chen, J., & Chaikof, E. L. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122464 · Cited by 46
Sosnowska, B., Stępińska, J., Mitkowski, P. P., Bielecka-Dabrowa, A. M., Bobrowska, B., Budzianowski, J., Burchardt, P., Chlebus, K., Dobrowolski, P., Gąsior, M., et al. (2024) · Archives of Medical Science · doi:10.5114/aoms/183522 · Cited by 50
Lipid lowering with inclisiran: a real-world single-centre experience
Padam, P., Barton, L., Wilson, S., David, A., Walji, S., de Lorenzo, F., Ray, K. K., Jones, B., & Cegla, J. (2022) · Open Heart · doi:10.1136/openhrt-2022-002184 · Cited by 41
Self-citationNanotechnology-enabled gene delivery for cancer and other genetic diseases
Jiang, T., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2200246 · Cited by 45
The evolving landscape of PCSK9 inhibition in cancer
Oza, P. P., & Kashfi, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175721 · Cited by 43
Donato, M., Ferri, N., Lupo, M. G., Faggin, E., & Rattazzi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218263 · Cited by 44
Primary hyperoxaluria type 1: novel therapies at a glance
Bacchetta, J., & Lieske, J. C. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab245 · Cited by 43
Lp(a): a New Pathway to Target?
Nurmohamed, N. S., Kraaijenhof, J. M., & Stroes, E. S. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01060-4 · Cited by 43
Pirillo, A., Catapano, A. L., & Norata, G. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00972-x · Cited by 41
Katzmann, J. L., Cupido, A. J., & Laufs, U. (2022) · Metabolites · doi:10.3390/metabo12010070 · Cited by 41
Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking
Mangla, P., Vicentini, Q., & Biscans, A. (2023) · Cells · doi:10.3390/cells12182253 · Cited by 44
PCSK9 inhibitors: current status and emerging frontiers in lipid control
Agnello, F. G., Mauro, M. S., Rochira, C., Landolina, D., Finocchiaro, S., Greco, A., Ammirabile, N., Raffo, C., Mazzone, P. M., Spagnolo, M., et al. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2288169 · Cited by 43
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy
Corvigno, S., Liu, Y., Bayraktar, E., Stur, E., Bayram, N. N., Ahumada, A. L., Nagaraju, S., Rodriguez‐Aguayo, C., Chen, H., Vu, T. C., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00556-3 · Cited by 39
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
Mitochondrion-targeted RNA therapies as a potential treatment strategy for mitochondrial diseases
Chernega, T., Choi, J., Salmena, L., & Andreazza, A. C. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.012 · Cited by 39
Pachamuthu, K., Mori, S., Matsuda, S., Erande, N. D., Datta, D., Willoughby, J. L. S., Taneja, N., O′Shea, J., Bisbe, A., Manoharan, R. M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01337 · Cited by 41
Dutka, M., Zimmer, K., Ćwiertnia, M., Ilczak, T. P., & Bobiński, R. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10409-7 · Cited by 46
siRNA drug Leqvio (inclisiran) to lower cholesterol
Migliorati, J. M., Jin, J., & Zhong, X. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.02.003 · Cited by 39
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
Zuurbier, L. C., Defesche, J. C., & Wiegman, A. (2021) · Genes · doi:10.3390/genes12081168 · Cited by 38
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Wilkinson, M. J., Bajaj, A., Brousseau, M. E., & Taub, P. R. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032031 · Cited by 37
Reijman, M. D., Schweizer, A., Peterson, A. L. H., Bruckert, E., Stratz, C., Defesche, J. C., Hegele, R. A., & Wiegman, A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac025 · Cited by 37
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran
Soffer, D. E., Stoekenbroek, R. M., & Plakogiannis, R. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.009 · Cited by 37
Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics
Addison, M., Ranasinghe, P. D., & Webb, D. J. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.19430 · Cited by 37
Xie, S., Galimberti, F., Olmastroni, E., Carugo, S., Catapano, A. L., & Casula, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120420 · Cited by 40
Advances in familial hypercholesterolaemia in children
Reijman, M. D., Kusters, D. M., & Wiegman, A. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00095-x · Cited by 38
The emerging landscape of peptide-based inhibitors of PCSK9
Tombling, B. J., Zhang, Y., Huang, Y., Craik, D. J., & Wang, C. K. L. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.903 · Cited by 34
Korneva, V., Kuznetsova, T. Y., & Julius, U. (2021) · Biomedicines · doi:10.3390/biomedicines9091271 · Cited by 35
PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
Kuzmich, N. N., Andresyuk, E., Porozov, Y. B., Tarasov, V. V., MIu, S., Preferanskaya, N., Veselov, V. V., & Alyautdin, R. N. (2022) · Molecules · doi:10.3390/molecules27020434 · Cited by 35
Guenther, D. C., Mori, S., Matsuda, S., Gilbert, J. A., Willoughby, J. L. S., Hyde, S., Bisbe, A., Jiang, Y., Agarwal, S., Madaoui, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c01679 · Cited by 35
Köenig, W., Conde, L. G., Landmesser, U., Leiter, L. A., Ray, K. K., Schwartz, G. G., Wright, R. S., Han, J., & Raal, F. J. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07413-0 · Cited by 37
Self-citationLipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 35
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
Burnett, J. R., & Hooper, A. J. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2267972 · Cited by 36
Bosco, G., Barbagallo, F. D. G., Marco, M. D., Scilletta, S., Miano, N., Esposto, S., Pennisi, G., Prezzavento, S., Gallo, A., Francesco, E. M. D., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.05.008 · Cited by 35
Groner, J., Göpferich, A. M., & Breunig, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.034 · Cited by 34
Cicero, A. F. G., Fogacci, F., Zambon, A., Toth, P. P., & Borghi, C. (2022) · American Heart Journal Plus: Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100127 · Cited by 34
Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis
Alannan, M., Fatrouni, H., Trézéguet, V., Dittrich-Domergue, F., Moreau, P., Siegfried, G., Liet, B., Khatib, A., Grosset, C. F., Badran, B. M., et al. (2022) · Cells · doi:10.3390/cells12010062 · Cited by 35
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 34
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 36
Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Greco, M. F., Sirtori, C. R., Corsini, A., Владиславович, Е. М., Sampietro, T., & Ruscica, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072103 · Cited by 33
Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
Hawner, M., & Ducho, C. (2020) · Molecules · doi:10.3390/molecules25245963 · Cited by 31
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 35
RNA Silencing in the Management of Dyslipidemias
Henney, N. C., Banach, M., & Penson, P. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00968-7 · Cited by 32
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Jia, X., Rifai, M. A., Saeed, A., Ballantyne, C. M., & Virani, S. S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s275739 · Cited by 34
A Graph Neural Network Approach for the Analysis of siRNA-Target Biological Networks
Rosa, M. L., Fiannaca, A., Paglia, L. L., & Urso, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214211 · Cited by 35
Ballard‐Hernandez, J., & Sall, J. (2023) · Nursing Clinics of North America · doi:10.1016/j.cnur.2023.05.002 · Cited by 36
Efficacy and Safety of Inclisiran in Asian Patients
Huo, Y., Lesogor, A., Lee, C. W., Chiang, C.-E., Mena-Madrazo, J., Poh, K. K., Jeong, M. H., Maheux, P., Zhang, M., Wei, S., et al. (2024) · JACC: Asia · doi:10.1016/j.jacasi.2023.09.006 · Cited by 31
A promising therapy for fatty liver disease: PCSK9 inhibitors
Han, L., Wu, L., Yin, Q., Li, L., Zheng, X., Du, S., Huang, X., Bai, L., Wang, Y., & Bian, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155505 · Cited by 31
Gene therapy then and now: A look back at changes in the field over the past 25 years
Wang, D., Stevens, G., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.040 · Cited by 34
Distribution and biotransformation of therapeutic antisense oligonucleotides and conjugates
Weidolf, L. O. G., Björkbom, A., Dahlén, A., Elebring, M., Gennemark, P., Hölttä, M., Janzén, D. L. I., Li, X., & Andersson, S. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.002 · Cited by 31
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Self-citationSmall circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing
Jahns, H., Degaonkar, R., Podbevšek, P., Gupta, S., Bisbe, A., Aluri, K. C., Szeto, J., Kumar, P., LeBlanc, S., Racie, T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab724 · Cited by 33
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 31
Metadata
- Authors
- Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., & Kastelein, J. J. P.
- Affiliations
- University of the Witwatersrand (ZA)
- Medpace (United States) (US)
- From the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (F.J.R.); the Medicines Company, Zurich, Switzerland (D.K.); the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London (K.K.R.); Medpace Reference Laboratories, Cincinnati (T.T.); Deutsches Herzzentrum München, Technische Universität München, and German Center for Cardiovascular Research, Munich Heart Alliance, Munich (W.K.), and the...
- Mayo Clinic (US)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1520-1530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3011005820
- Semantic Scholar
- cd7f15bcb062953bf710c34645a08f7b4818c4d9
- Cited by
- 818
- References
- 52
- Citations by year
- 2026: 88 · 2025: 126 · 2024: 142 · 2023: 154 · 2022: 140 · 2021: 111 · 2020: 56
- FWCI
- 105.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, heterozygous familial hypercholesterolemia, PCSK9 inhibition, siRNA, LDL cholesterol lowering, atherosclerotic cardiovascular disease prevention, hypercholesterolemia treatment, lipid-lowering therapy, PCSK9 monoclonal antibodies
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type II, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Treatment Outcome, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
